Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Indegene Limited ( (IN:INDGN) ) has shared an update.
Indegene Limited’s wholly owned unit, Indegene Healthcare UK Limited, has signed a share purchase agreement to acquire 100% of DT Associates Research and Consulting Services Limited, UK, from ILSL Holdings, Inc., and Trilogy Writing and Consulting Limited, UK, from Trilogy Writing and Consulting GmbH. Following completion, both UK-based targets will become wholly owned subsidiaries of Indegene Healthcare UK Limited, consolidating Indegene’s control over these specialist consulting and writing entities and further strengthening its operating footprint in the UK healthcare services market.
The company notified the stock exchanges under Regulation 30 of the SEBI Listing Regulations and indicated that additional disclosure details are available via an annexure and on its website. The move underscores Indegene’s ongoing inorganic expansion strategy via its international subsidiaries, potentially enhancing service breadth and market positioning for stakeholders across its global healthcare and life sciences client base.
More about Indegene Limited
Indegene Limited is a Bengaluru-headquartered company operating in the healthcare and life sciences services space, providing technology-enabled solutions to global clients. Through its network of wholly owned subsidiaries in Ireland and the UK, the company focuses on specialized consulting, research, and related services for regulated healthcare markets.
Average Trading Volume: 20,468
Technical Sentiment Signal: Sell
Current Market Cap: 119.2B INR
Find detailed analytics on INDGN stock on TipRanks’ Stock Analysis page.